Table 1:

Demographic and clinical characteristics of study participants.

		MS N = 95	HC N = 17
Mean Age (SD), years		45.2 (10.5)	42.2 (13.7)
Female sex (%)		66 (69.5)	11 (64.7)
Median Disease Duration [min-max], years		11.4 [0.4-47.8]	n/a
Median Number of Relapses in Past 12 months [min-max]		0 [0–3]	n/a
Relapses Treated with Corticosteroids in Past 30 days (%)		4 (4.2)	n/a
Clinical phenotype (%)			n/a
Relapsing-remitting		76 (80)
Secondary Progressive		8 (8.4)
Primary Progressive		11 (11.6)
Disease	None	19 (20)	n/a
	Interferon	2 (2.1)	n/a
	Glatiramer Acetate	7 (7.4)	n/a
	Natalizumab	12 (12.6)	n/a
	Teriflunomide	2 (2.1)	n/a
Modifying Therapy (%)	SIP Modulator	9 (9.5)	n/a
	Fumarates	13 (13.7)	n/a
	Anti-CD-20 Therapy	30 (31.6)	n/a
	Corticosteroids	0	n/a
	Other	1 (1.1)	n/a
Disability Scales	Median EDSS [min-max]	2.5 [0–6.5]	n/a
	Median 9HPT [min-max]	22.6 [15.6-425.7]	19.9 [16.8–29.5]
	Median T25W [min-max]	5.3* [3.2–161]	4.3* [3.6–53]
	Mean SDMT (SD)	53.9 (15.1)	56.8(11.2)
	Mean PASAT (SD)	45 [0–60]	46 [15–60]

HC = healthy control, MS = multiple sclerosis, SD = standard deviation. EDSS = Expanded Disability Status Scale, 9HPT = Nine Hole Peg Test (in seconds), T25W = Timed 25-foot walk (in seconds), SDMT = Symbol Digit Modalities Test (# correct), PASAT (# correct).

^*= p < 0.05 for comparison of HC and MS

Kruskall-Wallis or Wilcoxon rank sum tests for values showing medians, t-test for those showing means, and Chi-square or Fisher’s exact test for those showing proportions. Note, statistical tests comparing groups for disease modifying therapies not performed due to lack of clinical relevance.